BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27468199)

  • 1. Preoperative defining system for pancreatic head cancer considering surgical resection.
    Yang SJ; Hwang HK; Kang CM; Lee WJ
    World J Gastroenterol; 2016 Jul; 22(26):6076-82. PubMed ID: 27468199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Pancreatic Head Cancer with Portal Venous Involvement Really Borderline Resectable? Appraisal of an Upfront Surgery Series.
    Ohgi K; Yamamoto Y; Sugiura T; Okamura Y; Ito T; Ashida R; Aramaki T; Uesaka K
    Ann Surg Oncol; 2017 Sep; 24(9):2752-2761. PubMed ID: 28685356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma.
    Karabicak I; Satoi S; Yanagimoto H; Yamamoto T; Hirooka S; Yamaki S; Kosaka H; Inoue K; Matsui Y; Kon M
    J Hepatobiliary Pancreat Sci; 2016 Dec; 23(12):750-755. PubMed ID: 27794194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study.
    Miura T; Hirano S; Nakamura T; Tanaka E; Shichinohe T; Tsuchikawa T; Kato K; Matsumoto J; Kondo S
    Surgery; 2014 Mar; 155(3):457-67. PubMed ID: 24462074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.
    Kang CM; Lee SH; Hwang HK; Yun M; Lee WJ
    Medicine (Baltimore); 2016 Mar; 95(9):e2595. PubMed ID: 26945350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer.
    Miyazaki M; Yoshitomi H; Takano S; Shimizu H; Kato A; Yoshidome H; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Ohtuka M
    Langenbecks Arch Surg; 2017 May; 402(3):447-456. PubMed ID: 28361216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Factors influencing survival of patients with cancer of the pancreatic head after resection].
    Gao CT; Li HK; Li Q
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):554-7. PubMed ID: 19950708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?
    Nakamura T; Asano T; Okamura K; Tsuchikawa T; Murakami S; Kurashima Y; Ebihara Y; Noji T; Nakanishi Y; Tanaka K; Shichinohe T; Hirano S
    J Gastrointest Surg; 2019 May; 23(5):990-996. PubMed ID: 30242645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA19-9 as a predictor of resectability in patients with borderline resectable pancreatic cancer.
    He Z; Lu H; Du X; Hu W; Zhaoda BT
    Hepatogastroenterology; 2013 Jun; 60(124):900-3. PubMed ID: 23321027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma.
    Gu X; Zhou R; Li C; Liu R; Zhao Z; Gao Y; Xu Y
    BMC Cancer; 2019 May; 19(1):456. PubMed ID: 31092213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors affecting survival after pancreaticoduodenectomy for pancreatic adenocarcinoma (single center experience).
    El Nakeeb A; El Shobary M; El Dosoky M; Nabeh A; El Sorogy M; El Eneen AA; abu Zeid M; Elwahab MA
    Hepatogastroenterology; 2014; 61(133):1426-38. PubMed ID: 25436321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
    Wang G; Zhou D
    Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.
    Richter A; Niedergethmann M; Sturm JW; Lorenz D; Post S; Trede M
    World J Surg; 2003 Mar; 27(3):324-9. PubMed ID: 12607060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer.
    Okada K; Uemura K; Kondo N; Sumiyoshi T; Seo S; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Murakami Y; Takahashi S
    Pancreatology; 2021 Apr; 21(3):606-612. PubMed ID: 33648880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of factors influencing recurrence and metastasis following curative resection of pancreatic ductal adenocarcinoma].
    Xie YB; Zhao P; Wang CF; Shan Y; Zhao DB; Liu Q; Bai XF
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):686-9. PubMed ID: 19173911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
    Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
    J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.